Association of low serum levels of apolipoprotein A-I with adverse outcomes in patients with nonischemic heart failure.

[1]  P. Ponikowski,et al.  Autonomic imbalance and immune activation in chronic heart failure - pathophysiological links. , 2006, Cardiovascular research.

[2]  P. Barter,et al.  The rationale for using apoA‐I as a clinical marker of cardiovascular risk , 2006, Journal of internal medicine.

[3]  Marc A Pfeffer,et al.  Controversies in ventricular remodelling , 2006, The Lancet.

[4]  K. Watson,et al.  High-density lipoprotein function recent advances. , 2005, Journal of the American College of Cardiology.

[5]  P. Barter,et al.  Antiinflammatory Properties of HDL , 2004 .

[6]  D. Galaris,et al.  The possible role of oxidative stress in heart failure and the potential of antioxidant intervention. , 2003, Medical science monitor : international medical journal of experimental and clinical research.

[7]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[8]  Douglas L Mann,et al.  Inflammatory mediators and the failing heart: past, present, and the foreseeable future. , 2002, Circulation research.

[9]  James F Sallis,et al.  AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. , 2002, Circulation.

[10]  A. von Eckardstein,et al.  HDL and arteriosclerosis: beyond reverse cholesterol transport. , 2002, Atherosclerosis.

[11]  E. Antman,et al.  ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .

[12]  N. Hyka,et al.  Articles on similar topics can be found in the following Blood collections , 2013 .

[13]  M. Domanski,et al.  The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. , 2000, Journal of the American College of Cardiology.

[14]  K. Kugiyama,et al.  Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. , 1998, Circulation.

[15]  M. Munger,et al.  Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 1996, The American journal of cardiology.

[16]  D. Levy,et al.  Survival After the Onset of Congestive Heart Failure in Framingham Heart Study Subjects , 1993, Circulation.

[17]  P. Wilson,et al.  Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. , 1986, JAMA.

[18]  Y. Sakai,et al.  Quantitation of apolipoprotein A-I in pooled human serum by single radial immunodiffusion and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. , 1984, Analytical biochemistry.

[19]  A. Zinsmeister,et al.  Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease. , 1983, The New England journal of medicine.

[20]  R Gorlin,et al.  Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. , 1976, The American journal of cardiology.

[21]  A. Clauss,et al.  Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens , 1957 .